Strong evidence supports that the knockdown of NFKBIA confers partial resistance to erlotinib in lung cancer cell lines through elevated levels of NF-κB and that this resistance can be reversed by the inhibition of NF-κB or by the overexpression of NFKBIA (Table 1) [1,87]. This evidence concerns the gene NFKBIA and lung carcinoma.